Toll-like receptors in Borrelia burgdorferi-induced inflammation

Clinical Microbiology and Infection

Volumn 12, Issue 8, 2006, Pages 705-717

  Singh, S K ^a   Girschick, Hermann J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Borrelia burgdorferi; Inflammation; Review; Spirochaetal persistence; Tick borne disease; Toll like receptors

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL DNA; CD14 ANTIGEN; CYTOKINE; FLAGELLIN; LIPID BINDING PROTEIN; LIPOPROTEIN; LYME DISEASE VACCINE; METALLOPROTEINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2;

ANTIBIOTIC RESISTANCE; ANTIGEN RECOGNITION; BORRELIA BURGDORFERI; CELL STIMULATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TARGETING; HOST CELL; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INFECTION SENSITIVITY; INNATE IMMUNITY; LYME DISEASE; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

BORRELIA; BORRELIA BURGDORFERI;

EID: 33745588825     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01440.x     Document Type: Review

References (106)

1. Stein D, Roth S, Vogelsang E, Nusslein-Volhard C. The polarity of the dorsoventral axis in the Drosophila embryo is defined by an extracellular signal. Cell 1991; 65: 725-735.
2. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-983.
3. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-561.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
5. Werling D, Jungi TW. TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 2003; 91: 1-12.
6. Wooten RM, Morrison TB, Weis JH, Wright SD, Thieringer R, Weis JJ. The role of CD14 in signaling mediated by outer membrane lipoproteins of Borrelia burgdorferi. J Immunol 1998; 160: 5485-5492.
7. Seifert R, Schultz G, Richter-Freund M et al. Activation of superoxide formation and lysozyme release in human neutrophils by the synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides. Biochem J 1990; 267: 795-802.
8. Burns MJ, Sellati TJ, Teng EI, Furie MB. Production of interleukin-8 (IL-8) by cultured endothelial cells in response to Borrelia burgdorferi occurs independently of secreted IL-1 and tumor necrosis factor alpha and is required for subsequent transendothelial migration of neutrophils. Infect Immun 1997; 65: 1217-1222.
9. Marietta EV, Weis JJ, Weis JH. CD28 expression by mouse mast cells is modulated by lipopolysaccharide and outer surface protein A lipoprotein from Borrelia burgdorferi. J Immunol 1997; 159: 2840-2848.
10. Tai KF, Ma Y, Weis JJ. Normal human B lymphocytes and mononuclear cells respond to the mitogenic and cytokine-stimulatory activities of Borrelia burgdorferi and its lipoprotein OspA. Infect Immun 1994; 62: 520-528.
11. Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int 1996; 16: 125-132.
12. Girschick HJ, Meister S, Karch H, Huppertz HI. Borrelia burgdorferi downregulates ICAM-1 on human synovial cells in vitro. Cell Adhes Commun 1999; 7: 73-83.
13. Singh SK, Girschick HJ. Molecular survival strategies of the Lyme disease spirochete Borrelia burgdorferi. Lancet Infect Dis 2004; 4: 575-583.
14. Medzhitov R, Janeway CA. Innate immunity: The virtues of a nonclonal system of recognition. Cell 1997; 91: 295-298.
15. Teixeira MM, Almeida IC, Gazzinelli RT. Introduction: Innate recognition of bacteria and protozoan parasites. Microbes Infect 2002; 4: 883-886.
16. Armant MA, Fenton MJ. Toll-like receptors: A family of pattern-recognition receptors in mammals. Genome Biol 2002; 3: REVIEWS3011.
17. Pierer M, Rethage J, Seibl R et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172: 1256-1265.
18. Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 2001; 11: 304-311.
19. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002; 195: 559-570.
20. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
21. Huang Q, Liu D, Majewski P et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294: 870-875.
22. Mantovani A. The chemokine system: Redundancy for robust outputs. Immunol Today 1999; 20: 254-257.
23. Laudanna C, Kim JY, Constantin G, Butcher E. Rapid leukocyte integrin activation by chemokines. Immunol Rev 2002; 186: 37-46.
24. Singh SK, Morbach H, Nanki T, Girschick HJ. Differential expression of chemokines in synovial cells exposed to different Borrelia burgdorferi isolates. Clin Exp Rheumatol 2005; 23: 311-322.
25. Singh SK, Morbach H, Nanki T, Faber C, Baar V, Girschick HJ. Differential expression of matrix metalloproteinases and cyclooxygenases in synovial cells exposed to Borrelia burgdorferi. Inflamm Res 2004; 53: 689-696.
26. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589: 1-13.
27. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
28. Rescigno M, Granucci F, Citterio S, Foti M, Ricciardi-Castagnoli P. Coordinated events during bacteria-induced DC maturation. Immunol Today 1999; 20: 200-203.
29. Sallusto F, Palermo B, Lenig D et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 1617-1625.
30. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
31. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1: 199-205.
32. Takeuchi O, Sato S, Horiuchi T et al. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-14.
33. Alexopoulou L, Thomas V, Schnare M et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002; 8: 878-884.
34. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
35. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-1103.
36. Takeuchi O, Kawai T, Muhlradt PF et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13: 933-940.
37. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
38. Ozinsky A, Underhill DM, Fontenot JD et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97: 13766-13771.
39. Nagai Y, Akashi S, Nagafuku M et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-672.
40. Visintin A, Mazzoni A, Spitzer JA, Segal DM. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA 2001; 98: 12156-12161.
41. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: Cell surface receptor and differentiation marker. Immunol Today 1993; 14: 121-125.
42. Lien E, Sellati TJ, Yoshimura A et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999; 274: 33419-33425.
43. Diterich I, Rauter C, Kirschning CJ, Hartung T. Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression. Infect Immun 2003; 71: 3979-3987.
44. Takayama K, Rothenberg RJ, Barbour AG. Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1987; 55: 2311-2313.
45. Fraser CM, Casjens S, Huang WM et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997; 390: 580-586.
46. Belisle JT, Brandt ME, Radolf JD, Norgard MV. Fatty acids of Treponema pallidum and Borrelia burgdorferi lipoproteins. J Bacteriol 1994; 176: 2151-2157.
47. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999; 11: 19-22.
48. Ma Y, Weis JJ. Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties. Infect Immun 1993; 61: 3843-3853.
49. Steere AC, Sikand VK, Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339: 209-215.
50. Brandt ME, Riley BS, Radolf JD, Norgard MV. Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect Immun 1990; 58: 983-991.
51. Braun V, Rehn K. Chemical characterization, spatial distribution and function of a lipoprotein (murein-lipoprotein) of the E. coli cell wall. The specific effect of trypsin on the membrane structure. Eur J Biochem 1969; 10: 426-438.
52. Weis JJ, Ma Y, Erdile LF. Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: Dependence on lipid modification. Infect Immun 1994; 62: 4632-4636.
53. Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999; 285: 732-736.
54. Muhlradt PF, Meyer H, Jansen R. Identification of S-(2,3-dihydroxypropyl) cystein in a macrophage-activating lipopeptide from Mycoplasma fermentans. Biochemistry 1996; 35: 7781-7786.
55. Wooten RM, Modur VR, McIntyre TM, Weis JJ. Borrelia burgdorferi outer membrane protein A induces nuclear translocation of nuclear factor-kappa B and inflammatory activation in human endothelial cells. J Immunol 1996; 157: 4584-4590.
56. Ma Y, Seiler KP, Tai KF, Yang L, Woods M, Weis JJ. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect Immun 1994; 62: 3663-3671.
57. Norgard MV, Arndt LL, Akins DR, Curetty LL, Harrich DA, Radolf JD. Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-kappa B. Infect Immun 1996; 64: 3845-3852.
58. Morrison TB, Weis JH, Weis JJ. Borrelia burgdorferi outer surface protein A (OspA) activates and primes human neutrophils. J Immunol 1997; 158: 4838-4845.
59. Flo TH, Halaas O, Torp S et al. Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol 2001; 69: 474-481.
60. Wang G, Ma Y, Buyuk A, McClain S, Weis JJ, Schwartz I. Impaired host defense to infection and Toll-like receptor 2-independent killing of Borrelia burgdorferi clinical isolates in TLR2-deficient C3H/HeJ mice. FEMS Microbiol Lett 2004; 231: 219-225.
61. Wang G, Ojaimi C, Iyer R et al. Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice. Infect Immun 2001; 69: 4303-4312.
62. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-4537.
63. Barthold SW, Sidman CL, Smith AL. Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. Am J Trop Med Hyg 1992; 47: 605-613.
64. Schaible UE, Wallich R, Kramer MD et al. Protection against Borrelia burgdorferi infection in SCID mice is conferred by presensitized spleen cells and partially by B but not T cells alone. Int Immunol 1994; 6: 671-681.
65. Barthold SW, deSouza M, Feng S. Serum-mediated resolution of Lyme arthritis in mice. Lab Invest 1996; 74: 57-67.
66. Muzio M, Polntarutti N, Bosisio D, Prahladan MK, Mantovani A. Toll like receptor family (TLT) and signalling pathway. Eur Cytokine Netw 2000; 11: 489-490.
67. Barthold SW, de Souza M. Exacerbation of Lyme arthritis in beige mice. J Infect Dis 1995; 172: 778-784.
68. Rasley A, Anguita J, Marriott I. Borrelia burgdorferi induces inflammatory mediator production by murine microglia. J Neuroimmunol 2002; 130: 22-31.
69. Gebbia JA, Coleman JL, Benach JL. Selective induction of matrix metalloproteinases by Borrelia burgdorferi via toll-like receptor 2 in monocytes. J Infect Dis 2004; 189: 113-119.
70. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107: 725-731.
71. Du Chateau BK, England DM, Callister SM, Lim LC, Lovrich SD, Schell RF. Macrophages exposed to Borrelia burgdorferi induce Lyme arthritis in hamsters. Infect Immun 1996; 64: 2540-2547.
72. Steere AC, Gibofsky A, Patarroyo ME, Winchester RJ, Hardin JA, Malawista SE. Chronic Lyme arthritis. Clinical and immunogenetic differentiation from rheumatoid arthritis. Ann Intern Med 1979; 90: 896-901.
73. Lim LC, England DM, DuChateau BK et al. Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect Immun 1994; 62: 2825-2833.
74. Seibl R, Birchler T, Loeliger S et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 1221-1227.
75. Kyburz D, Rethage J, Seibl R et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003; 48: 642-650.
76. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430: 257-263.
77. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 1990; 5: 1095-1097.
78. Hultmark D. Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. Biochem Biophys Res Commun 1994; 199: 144-146.
79. Beutler B, Du Hoebe KX, Ulevitch RJ. How we detect microbes and respond to them: The Toll-like receptors and their transducers. J Leukoc Biol 2003; 74: 479-485.
80. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-979.
81. Adachi O, Kawai T, Takeda K et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9: 143-150.
82. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000; 165: 5392-5396.
83. Seki E, Tsutsui H, Tsuji NM et al. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol 2002; 169: 3863-3868.
84. Scanga CA, Aliberti J, Jankovic D et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002; 168: 5997-6001.
85. Feng CG, Scanga CA, Collazo-Custodio CM et al. Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to Mycobacterium avium infection not exhibited by Toll-like receptor 2 (TLR2)- and TLR4-deficient animals. J Immunol 2003; 171: 4758-4764.
86. Joosten LA, Koenders MI, Smeets RL et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: Critical role of myeloid differentiation factor 88. J Immunol 2003; 171: 6145-6153.
87. Bolz DD, Sundsbak RS, Ma Y et al. MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. J Immunol 2004; 173: 2003-2010.
88. Akira S, Hoshino K. Myeloid differentiation factor 88-dependent and -independent pathways in toll-like receptor signaling. J Infect Dis 2003; 187 (suppl 2): S356-S363.
89. Liu N, Montgomery RR, Barthold SW, Bockenstedt LK. Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in Borrelia burgdorferi-infected mice. Infect Immun 2004; 72: 3195-3203.
90. Toshchakov V, Jones BW, Perera PY et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 2002; 3: 392-398.
91. Yamamoto M, Sato S, Hemmi H et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329.
92. Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413: 78-83.
93. Horng T, Barton GM, Medzhitov R. TIRAP: An adapter molecule in the Toll signaling pathway. Nat Immunol 2001; 2: 835-841.
94. Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB. Toll-like receptor 4 is required for optimal development of Th2 immune responses: Role of dendritic cells. J Immunol 2002; 168: 4524-4530.
95. Kobayashi K, Inohara N, Hernandez LD et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002; 416: 194-199.
96. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989; 264: 10867-10871.
97. Schutt C. Fighting infection: The role of lipopolysaccharide binding proteins CD14 and LBP. Pathobiology 1999; 67: 227-229.
98. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988; 141: 547-552.
99. Hirschfeld M, Kirschning CJ, Schwandner R et al. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999; 163: 2382-2386.
100. Sellati TJ, Bouis DA, Kitchens RL et al. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. J Immunol 1998; 160: 5455-5464.
101. Kusunoki T, Hailman E, Juan TS, Lichenstein HS, Wright SD. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 1995; 182: 1673-1682.
102. Hailman E, Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179: 269-277.
103. Lin B, Noring R, Steere AC, Klempner MS, Hu LT. Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease. J Infect Dis 2000; 181: 1185-1188.
104. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558-9563.
105. Yang L, Weis JH, Eichwald E, Kolbert CP, Pershing DH, Weis JJ. Heritable susceptibility to severe Borrelia burgdorferi-induced arthritis is dominant and is associated with persistence of large numbers of spirochaetes in tissues. Parasitol Today 1994; 10: 128.
106. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330: 229-234.